Factors Associated with Uptake of Isoniazid Preventive Therapy among Children under 5 Years Tuberculosis Contacts in Greater Kibaale, Uganda

Tenywa Isaac¹ and Omona Kizito^2,

¹MPH Specialist, Faculty of Health Sciences, Uganda Martyrs University

²Lecturer, Faculty of Health Sciences, Uganda Martyrs University

Cite this paper

Tenywa Isaac and Omona Kizito. Factors Associated with Uptake of Isoniazid Preventive Therapy among Children under 5 Years Tuberculosis Contacts in Greater Kibaale, Uganda. American Journal of Public Health Research. 2022; 10(2):76-89. doi: 10.12691/AJPHR-10-2-5

Abstract

Isoniazid Preventive Therapy (IPT) is a chemoprophylaxis which reduces the risk of the first episode of TB occurring in people exposed to an infection or with latent infection and the risk of a recurrent episode of TB. WHO recommends isoniazid taken at a daily dose of 5 mg/kg (maximum 300 mg) for at least six months. In Uganda, only 16% of 15957 children contacts of smear-positive TB index cases are on preventive treatment. The objective of this study was to assess factors associated with uptake of isoniazid preventive therapy among children under 5 years’ tuberculosis contacts in Greater Kibaale. An analytical cross-sectional study design utilizing both quantitative and qualitative methods was conducted among 207 children under 5 years’ tuberculosis contacts. They were recruited using convenience sampling methods. The caregiver of the children completed a structured questionnaire in English and translated into Lunyoro. Data was single-entered and analyzed using SPSS version 22. Bivariate, univariate and multivariate Logistic regression analysis methods were used to identify factors associated with uptake of isoniazid preventive. Of the 207 participants, the uptake IPT was low at 36.7%. Being in the age group of 35-44 years (AOR=15.856, 95% CI: 11.568-27.115), being married, AOR=17.867, 95% CI: 4.631-215.769), p=.008) being separated (AOR=4.4.35, 95% CI; 1.056-6.530, p=0.047), having a monthly income of 40,000-100,000 shillings (AOR=9.917, 95% CI: 6.380-15.450, p=.000), finding it easy to talk to other people about TB problem AOR=.012, 95% CI: .004-.303, p=.007), not screening for TB (AOR=0.391, 95% CI: .242-.791, p=.000) and receiving continuous counselling (AOR=0.004, 95% CI: .001-.142, p=.002) were independently associated with uptake of isoniazid preventive. Conclusively, the level of uptake of IPT was low. Contact screening seems a good entry point for delivery of Isoniazid Preventive Therapy to at-risk children when routinely practised as recommended by WHO.

Keywords

Isoniazid Preventive Therapy (IPT), Tuberculosis (TB), health care, barriers, facilitators, quality of care

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	World Health Organization. Global tuberculosis report 2013. Geneva: WHO, 2018a.
[2]	World Health Organization. The Stop TB Strategy. Geneva: WHO, 2018b.
[3]	Semu, M., Fenta, T.G., Medhin, G. and Assefa, D. 2017. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study. BMC Infectious Diseases. 20 (7), pp.17-25.
[4]	World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis, Geneva: WHO, 2018c. Available at: http://apps.who.int/iris/bitstream/handle/10665/260494/9789241550079-eng.pdf.
[5]	Burmen, B., Mutai, K. and Malika, T. 2019. Isoniazid Preventative Therapy uptake for child household contacts of tuberculosis index cases, Kisumu County, Kenya, 2014-2015. Journal of public health in Africa, Vol. 10, Issue 1, 2019.
[6]	World Health Organization. Global tuberculosis control: a short update to the 2010 Report. Geneva: WHO, 2010.
[7]	Dye, C., Glaziou, P., Floyd, K. and Raviglione, M. Prospects for tuberculosis elimination. Annu Rev Public Health, 13(34), pp.271-86, 2014.
[8]	Mindachew, M., Deribew, A., Memiah, P. and Biadgilign, S. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan African Medical Journal, 14(17), pp.26, 2014.
[9]	Nyamathi, A. M. C. A., Nahid, P., Gregerson, P. and Leake, B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis, 7(10), pp. 775-82, 2016.
[10]	Szakacs, T. A., Wilson, D., Cameron, D. W., Clark, M., Kocheleff, P. and Muller, .F. J. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis, 13(6), pp. 6:97, 2016.
[11]	Fentahun, N., Wasihun, Y., Mamo, A. and Gebretsadik, L. A. Contact Screening and Isoniazid Preventive Therapy Initiation for Under-Five Children among Pulmonary Tuberculosis-Positive Patients in Bahir Dar Special Zone, Northwest Ethiopia: A Cross-Sectional Study. Tuberculosis research and treatment, 6(7), pp.346-75, 2020.
[12]	Omesa, E.N., Kathure, I.A., Masini, E., Mulwa, R., Maritim, A. and Owiti, P.O. Uptake of isoniazid preventive therapy and its associated factors among HIV positive patients in an urban health Centre, Kenya. East African Medical Journal, 93(10), pp.47-54, 2016.
[13]	Ministry of Health, National Guideline for the Management of Drug Resistant Tuberculosis, Kampala: Uganda, 2017. Available at: https://www.moh.gov.bt/wp-content/uploads/afd-files/2018/09/National-Guideline-For-The-Managment-of-Drug-Resistant-TB-2017.pdf.
[14]	Katende, J. N., Omona, K., User - provider perspectives to overcome the challenges of TB/HIV service integration at Mulago National Referral Hospital, Kampala. Afri Health Sci., 21(1): 248-53, 2021.
[15]	Omona, K., Laban, S. Factors associated with uptake of community client-led ART delivery model at Mulago adult HIV clinic, Mulago National Referral Hospital, Cogent Medicine, 8 (1), 2021.
[16]	Ministry of Health. MINISTRY OF HEALTH MANUAL OF THE NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME, 2nd Ed., Kampala: MOH, 2010. Available at: https://www.who.int/hiv/pub/guidelines/uganda_tb.pdf.
[17]	Tadesse, Y., Gebre, N., Daba, S., Gashu, Z., Habte, D., Hiruy, N., Negash, S., Melkieneh, K., Jerene, D., K Haile, Y., Kassie, Y., Melese, M. & G Suarez, P. Uptake of Isoniazid Preventive Therapy among Under-Five Children: TB Contact Investigation as an Entry Point. PloS one, 11(5), pp.155-525, 2016.
[18]	Adjobimey, M., Masserey, E., Adjonou, C., Gbénagnon, G., Schwoebel, V., Anagonou, S., and Zellweger, J. P. 2016. Implementation of isoniazid preventive therapy in children aged under 5 years exposed to tuberculosis in Benin. The international journal of tuberculosis and lung disease, 20(8); 1055-1059, 2016.
[19]	Egere, U., Sillah, A. and Togun, T. 2016. Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in the Gambia, International Journal of Tuberculosis and Lung Diseases, 6 (4), pp. 226-231, 2016.
[20]	Khaparde, K., Jethani, P., Dewan, P. K., Nair, S. A., Deshpande, M. R., Satyanarayana, S., Mannan, S. and Moonan, P. K. Evaluation of TB Case Finding through Systematic Contact Investigation, Chhattisgarh, India. Tuberculosis research and treatment, 6(7), pp.16-27, 2015.
[21]	Zawedde-Muyanja, S., Nakanwagi, A., Dongo, J. P., Sekadde, M. P., Nyinoburyo, R., Ssentongo, G., Detjen, A. K., Mugabe, F., Nakawesi, J., Karamagi, Y., Amuge, P., Kekitiinwa, A. and Graham, S. M. Decentralisation of child tuberculosis services increases case finding and uptake of preventive therapy in Uganda. The international journal of tuberculosis and lung disease 22(11), pp.1314-1321, 2018.
[22]	Nyathi, S., Dlodlo, R. A., Satyanarayana, S., Takarinda, K. C., Tweya, H., Hove, S., Matambo, R., Mandewo, W., Nyathi, K., Sibanda, E. and Harries, A. D. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PloS one, 14(10), pp.223-6, 2019.
[23]	Sabasaba, A., Mwambi, H., Somi, G., Ramadhani, A. & Mahande, M. J. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study. BMC Infectious Diseases, 19 (62), 2019.
[24]	Osman, M., Hesseling, A. C., Beyers, N., Enarson, D. A., Rusen, I. D. and Lombard, C. 2013. Impact of isoniazid preventive therapy on mortality among children less than 5 years old following exposure to tuberculosis at home in Guinea-Bissau: a prospective cohort study. BMJ Open, 3(3), pp.101-136, 2013.
[25]	Black, F., Amien, F. and Shea, J. An assessment of the isoniazid preventive therapy programme for children in a busy primary healthcare clinic in Nelson Mandela Bay Health District, Eastern Cape Province, South Africa. South African medical journal, 108(3), pp.217-223, 2018.
[26]	Okwara, F. N., Oyore, J. P., Were, F. N. and Gwer, S. Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya - a cohort study. BMC infectious diseases, 17(1), pp. 623, 2017.
[27]	Zelner, J. L., Murray, M. B., Becerra, M. C., Galea, J., Lecca, L., Calderon, R., Yataco, R., Contreras, C., Zhang, Z., Grenfell, B. T. and Cohen, T. Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis. American journal of respiratory and critical care medicine, 189(7), pp. 853-859, 2014.
[28]	Singh, M., Mynak, M., Kumar, L., Mathew, J. and Jindal, S. Prevalence and risk factors for transmission of infection among children in household contact with adults having pulmonary tuberculosis. Arch Dis Child, 90(6), pp. 624-628, 2015.
[29]	Singh, A.R., Kharate, A., Bhat, P., Kokane, A.M., Bali, S., Sahu, S., Verma, M., Nagar, M. and Kumar, MA.M.V. Isoniazid Preventive Therapy among Children Living with Tuberculosis Patients: Is It Working? A Mixed-Method Study from Bhopal, India. Journal of Tropical Pediatrics, 63, (4), pp. 274-285, 2017.
[30]	Jalo, R.I. 2020. Uptake of isoniazid preventive therapy for tuberculosis among HIV patients in Kano, Nigeria. Niger J Basic Clin Sci, 13(17), pp.57-63, 2020.
[31]	Anger, H. A., Proops, D., Harris, T. G., Li, J., Kreiswirth, B. N., Shashkina, E. and Ahuja, S. D. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Clin Infect Dis, 54(9), pp. 1287-1295, 2012.
[32]	Gebretnsae, H., Ayele, B.G. and Hadgu, T. Implementation status of household contact tuberculosis screening by health extension workers: assessment findings from programme implementation in Tigray region, northern Ethiopia. BMC Health Services Research 20(1), pp.72, 2020.
[33]	Belgaumkar, V., Chandanwale, A., Valvi, C. Barriers to screening and isoniazid preventive therapy for child contacts of tuberculosis patients. Int J Tuberc Lung Dis, 22(10), pp1179-1187, 2018.
[34]	Jacobson, K. B., Niccolai, L., Mtungwa, N., Moll, A. P., & Shenoi, S. V. It's about my life: facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS care, 29(7), pp.936-942, 2017.